Effect of IL-22 on DNA vaccine encoding LACK gene of Leishmania major in BALB/c mice

Experimental Parasitology

Volumn 134, Issue 3, 2013, Pages 341-348

  Hezarjaribi, Hajar Ziaee ^a   Ghaffarifar, Fatemeh ^a   Dalimi, Abdolhosein ^a   Sharifi, Zohreh ^b   Jorjani, Ogholniaz ^c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^c GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

DNA vaccine; IL 22; Leishmania major; PcLACK

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 22; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE; HUMORAL IMMUNITY; LEISHMANIA HOMOLOG OF RECEPTOR FOR ACTIVATED C KINASE GENE; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SURVIVAL RATE; TH1 CELL; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BODY WEIGHT; FEMALE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; INTERLEUKINS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTES; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SPLEEN; SURVIVAL RATE; VACCINES, DNA;

EID: 84877895172     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2013.03.012     Document Type: Article

References (42)

1. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994, 263:235-237.
2. Ahmed S.B., Bahloul C., Robbana C., Askri S., Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine Leishmaniasis due to L. major. Vaccine 2004, 22:1631-1639.
3. Antonio E., Coelho F., Tavares C., Fernandes A., Lima K., Silva C., Rodriguesjr J. Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (L) major infection. Parasitol. Res. 2006, 98:568-575.
4. Bhopale G.M. Development of a vaccine for Toxoplasmosis: current status. Microb. Infect. 2003, 5:457-462.
5. Boniface K., Bernard F.X., Garcia M., Gurney A.L., Lecron J.C., Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 2005, 174:3695-3702.
6. Bradford M.M. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
7. Bretscher P.A., Ogunremi O., Menon J. Distinct immunological states in murine cutaneous leishmaniasis by immunizing with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states. Behring. Inst. Mitteilungen. 1997, 98:1-11.
8. Conti P., Kempuraj D., Frydas S., Kandere K., Boucher W., Letourneau R., Madhappan B., Sagimoto K., Christodoulou S., Theoharides T.C. IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. Immunol. Lett. 2003, 88:171-174.
9. Dhiman R., Indramohan M., Barnes P.F., Nayak R.C., Paidipally P., Rao L.V., Vankayalapati R. IL22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J. Immunol. 2009, 183:6639-6645.
10. Dumoutier L., Leemans C., Lejeune D., Kotenko S.V., Renauld J.C. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J. Immunol. 2001, 167:3545-3549.
11. Duthie M.S., Raman V.S., Piazza F.M., Reed S.G. The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 2012, 30:134-141.
12. Farnandez-Botran R., Vetyickaz V. Methods in Cellular Immunology 2001, CRF Press LNC. 2nd ed.
13. Ghaffarifar F., Jorjani O., Sharifi Z., Dalimi A., Hassan Z., Tabatabaie F., Khoshzaban F., Ziaei Hezarjaribi H. Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major. APMIS 2012, 121:290-298.
14. Gurunathan S., Sacks D.L. Vaccination with DNA Encoding the Immunodominant LACK pParasite Antigen Confers Protective Immunity to Mice infected With Leishmania major. Exp. Med. 1997, 186:1137-1147.
15. Hoseinian Khosroshahi K., Ghaffarifar F., Sharifi Z., D'Souza S., Dalimi A., Hassan Z., Khoshzaban F. Comparing the effect of IL-12 genetic adjuvant and alum non-genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of Toxoplasma gondii. Parasitol. Res. 2012, 111:403-411.
16. Igwa D., Sakai M., Savan R. An unexpected discovery of two interferon gamma-like genes along with interleukin (IL)22 and -26 from teleost:IL-22 and -26 genes have been described for the first time outside mammals. Mol. Immunol. 2006, 43:999-1009.
17. Ivory C., Chadee K. DNA vaccines: designing strategies against parasitic infections. Genet. Vaccines Ther. 2004, 2:1-8.
18. Jorjani O., Ghaffarifar F., Dalimi A., Sharifi Z., Hassan Z.M. Cloning and expressen of recombinant plasmid containing LACK gene of Leishmania major (MHRO/IR/75/ER) in CHO cells. ISESCO J. Sci. Technol. 2012, 8:37-43.
19. Julia V., Glaichenhaus N. CD4 (+) Tcells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B 10.D2 mice. Infect. Immun. 1999, 67:3641-3644.
20. Kellum R.E. Treatment of cutaneous leishmaniasis with an interalesinonal drug (Pentostam). J. Am. Acad. Dermatol. 1986, 15:620.
21. Kemp M., Hey A.S., Bendtzen K., Kharazmi A., Theander T.G. Th1-like human T cell clones recognizing leishmania GP63 inhibit Leishmania (L).major in human macrophages. Scand. J. Immunol. 1994, 40:629-635.
22. Kofta W., Wedrychowicz H. C-DNA vaccination against parasitic Infection: advantages and disadvantages. Vet. Parasitol. 2001, 100:3-12.
23. Liu M.A. DNA vaccines: a review. J. Intern. Med. 2003, 253:402-410.
24. Lopez-Fuertes L., Perez-Jimenez E., Vila-Coro A.J., Sack F., Moreno S., Koning S.A., Junghans C., Wittig B., Timon M., Esteban M. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 2002, 21:247-257.
25. Maillard I., Launois P. Functional plasticity of the LACK-ractive V beta 4-V alpha 8 CD4(+) Tcells normally producing early IL-4 instructing Th2 cell development and susceptibility to leishmania major in BALB/c mice. Eur. J. Immunol. 2001, 31:1288-1296.
26. Mauel J. Vaccination against leishmania infections, Current drug targets-immune. Endocr. Metab. Disord. 2002, 2:201-226.
27. Mcsorley S., Proudfoot L.O., Donnel C.A., Liew F.Y. Immunology of murine Leishmanhasis. Clin. Dermatol. 1996, 14:451-464.
28. Mugneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E., Waldmann R., Locksley R.M., Glaichenhaus N. Expression cloning of a protective leishmania antigen. Science 1995, 268:563-566.
29. Munder M., Eichmann K., Modolell M. Alternative metabolic states in Murine macrophages reflected by the Nitric oxide synthase. Immunology 1998, 160:5347-5354.
30. Nagem R.A., Colau D., Dumoutier L., Renauld J.C., Ogata C., Polikarpov I. Crystal, structure of recombinant human interleukin-22. Stucture 2002, 10:1051-1062.
31. Perez-Jimenez E., Kochan G., Gherardi M.M., Esteban M. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect. 2006, 8(3):810-822.
32. Pitta M.G.R., Romano A., Cabantous S., Henri S., Hammad A., Kouriba B., Argiro L., El-Kheir M., Bucheton B., Mary C., El-Safi S.H., Dessein A. IL17 and IL22 are associated with Protection against human Kala azar caused by Leishmania donovani. J. Clin. Invest. 2009, 119:2379-2387.
33. Reed S.G. Leishmaniasis vaccination: targeting the source of infection. Exp. Med. 2001, 194:F7-F9.
34. Rodriguez F., Whitton J.L. Minireview, Enhancing DNA immunization. Virology 2000, 268:233-238.
35. Sasaki S., Takeshita F., Ke-qin X., Ishii N., Okuda K. Adjuvant formulation and delivery systems for DNA vaccines. Methods 2003, 31:243-254.
36. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with soluble extract of promastigotes. J. Immunol. 1987, 139:221-227.
37. Scott P. The role of TH1 and TH2 cells in experimental cutaneous Leishmaniasis. Exp. Parasitol. 1989, 68:369-372.
38. Tapia E., Perez-Jimenez E. The combination of DNA vectors expressing IL-12+IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect. 2003, 5:73-84.
39. Verma A., Prasad K.N., Singh A.K., Nyati K.K., Gupta R.K., Paliwal V.K. Evaluation of the MTT lymphocyte proliferation assay for the diagnosisof neurocysticercosis. J. Microbiol. Methods 2010, 81:175-178.
40. Webb J.R., Campos-Neto A., Ovendale P.J., Martin T.I., Stromberg E.J., Badaro R., Reed S.G. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 1998, 66:3279-3289.
41. Wolff J.A., Malone R.W., Williams P., Ascadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247:1465-1468.
42. Ziaee Hezarjarib H., Ghaffarifar F., Dalimi A., Sharifi Z. The survey of the effect of cytokine IL22 on the ulcer originated from L. major in BALB/c mice. J. Mazand Univ. Med. Sci. 2012, 12:285-294.